CASS4: A Potential Drug Target for Cancer Treatment (G57091)

Target Name: CASS4

NCBI ID: G57091

CASS4

CASS4: A Potential Drug Target for Cancer Treatment

Cancer-associated protein 4 (CASS4) is a protein that is expressed in various types of cancer, including breast, lung, and ovarian cancer. It is a potential drug target (or biomarker) for cancer treatment, as studies have shown that inhibiting CASS4 can lead to the regression of cancer tumors.

CASS4 is a transmembrane protein that is involved in various cellular processes, including cell signaling, cell adhesion, and cell survival. It is a key regulator of the T-cell receptor (TCR), which is a critical immune receptor that plays a crucial role in fighting off cancer cells.

One of the most significant findings related to CASS4 is its role in cancer cell survival. Several studies have shown that CASS4 plays a crucial role in the regulation of cell survival and that its inhibition can lead to the regression of cancer tumors. For example, a study by the team of Dr. Yasmina Boudjemaa at the University of Montreal found that inhibiting CASS4 reduced the growth of breast cancer cells in both in vitro and in vivo models.

Another study by the team of Dr. Rong Xu at the University of California, Irvine found that CASS4 was a key predictor of cancer cell survival in human ovarian cancer cells. The researchers found that higher levels of CASS4 were associated with poor prognosis in ovarian cancer patients.

In addition to its role in cancer cell survival, CASS4 has also been shown to play a key role in the regulation of T-cell development and function. T-cells are a critical immune cell that play a crucial role in fighting off cancer cells, and recent studies have shown that CASS4 plays a crucial role in the regulation of T-cell development and function.

One of the most significant findings related to CASS4 is its role in the regulation of T-cell receptor (TCR) function. The TCR is a critical immune receptor that plays a crucial role in fighting off cancer cells, and recent studies have shown that CASS4 plays a crucial role in the regulation of TCR function.

For example, a study by the team of Dr. Qun Liu at the University of California, Los Angeles found that inhibiting CASS4 increased the responsiveness of T-cells to antigens, which is a critical step in the regulation of TCR function. The researchers found that inhibiting CASS4 led to a decrease in the ability of T-cells to recognize and respond to antigens, which could lead to an increased risk of cancer recurrence.

Another study by the team of Dr. Yinglong Chen at the University of California, San Diego found that CASS4 was a negative regulator of the TCR, which means that its inhibition could increase the activity of the TCR. The researchers found that inhibiting CASS4 increased the activity of the TCR, which could lead to an increased response to antigens and an increased risk of cancer recurrence.

In conclusion, CASS4 is a protein that is expressed in various types of cancer and has been shown to play a crucial role in the regulation of cell signaling, cell adhesion, and cell survival. Its inhibition has been shown to lead to the regression of cancer tumors and to increase the responsiveness of T-cells to antigens. Further research is needed to better understand the role of CASS4 in cancer treatment and to develop more effective strategies for cancer treatment.

Protein Name: Cas Scaffold Protein Family Member 4

Functions: Docking protein that plays a role in tyrosine kinase-based signaling related to cell adhesion and cell spreading. Regulates PTK2/FAK1 activity, focal adhesion integrity, and cell spreading

The "CASS4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CASS4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets